Quest Diagnostics, Inc. (DGX) shares projected to rise by -0.03%

At the time of writing, Quest Diagnostics, Inc. [DGX] stock is trading at $157.47, up 6.85%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DGX shares have gain 5.44% over the last week, with a monthly amount glided 2.27%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Previously, Citigroup upgraded its rating to Buy on July 10, 2024, and elevated its price target to $165. On February 26, 2024, Leerink Partners initiated with a Market Perform rating and assigned a price target of $135 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $155 on February 07, 2024. Barclays initiated its recommendation with a Equal Weight and recommended $145 as its price target on January 03, 2024. BofA Securities upgraded its rating to Buy for this stock on December 12, 2023, and upped its price target to $160. In a note dated June 29, 2023, Piper Sandler initiated an Neutral rating.

For the past year, the stock price of Quest Diagnostics, Inc. fluctuated between $120.87 and $159.36. Currently, Wall Street analysts expect the stock to reach $157.42 within the next 12 months. Quest Diagnostics, Inc. [NYSE: DGX] shares were valued at $157.47 at the most recent close of the market. An investor can expect a potential drop of -0.03% based on the average DGX price forecast.

Analyzing the DGX fundamentals

According to Quest Diagnostics, Inc. [NYSE:DGX], the company’s sales were 9.54B for trailing twelve months, which represents an 8.41% jump. Gross Profit Margin for this corporation currently stands at 0.16% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.19 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.02.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 152.82 points at the first support level, and at 148.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 160.64, and for the 2nd resistance point, it is at 163.80.

Ratios To Look Out For

It is important to note that Quest Diagnostics, Inc. [NYSE:DGX] has a current ratio of 1.25. Also, the Quick Ratio is 1.17, while the Cash Ratio stands at 0.37. Considering the valuation of this stock, the price to sales ratio is 1.84, the price to book ratio is 2.59 and price to earnings (TTM) ratio is 21.14.

Transactions by insiders

Recent insider trading involved PREVOZNIK MICHAEL E, SVP & General Counsel, that happened on Aug 29 ’24 when 32551.0 shares were sold. SVP, Clinical Solutions, KUPPUSAMY KARTHIK completed a deal on Aug 28 ’24 to sell 1990.0 shares. Meanwhile, Officer PREVOZNIK MICHAEL E bought 32551.0 shares on Aug 29 ’24.

Related Posts